Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 28:5:15.
doi: 10.1186/s40959-019-0050-9. eCollection 2019.

Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group

Lisa M Kopp  1   2 , Richard B Womer  3 , Cindy L Schwartz  4 , David H Ebb  5 , Vivian I Franco  6 , David Hall  7 , Donald A Barkauskas  7   8 , Mark D Krailo  7   8 , Holcombe E Grier  9 , Paul A Meyers  10 , Leonard H Wexler  10 , Neyssa M Marina  11 , Katherine A Janeway  9 , Richard Gorlick  12 , Mark L Bernstein  13 , Steven E Lipshultz  6 ; Children’s Oncology Group
Affiliations

Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group

Lisa M Kopp et al. Cardiooncology. .

Abstract

Background: Dexrazoxane protects from lower-cumulative-dose doxorubicin cardiotoxicity, but the effect of dexrazoxane in children with sarcoma treated with higher-cumulative-dose doxorubicin is unknown.

Methods: We evaluated children with osteosarcoma (OS) on two Children's Oncology Group trials with higher dose doxorubicin (375-600 mg/m2) preceded by dexrazoxane (10:1 dexrazoxane:doxorubicin dosing). They were evaluated after the minimum expected treatment time (METT), defined as 28 weeks. Cardiotoxicity was identified by echocardiography and serum N-terminal pro-brain natriuretic peptide (NT-proBNP). Second malignant neoplasm (SMN) data was collected.

Results: All children had normal left ventricular (LV) systolic function as measured by LV fractional shortening and no heart failure. The end-diastolic septal thickness Z-scores (P < 0.01) and LV mass Z-scores (P < 0.01) were significantly smaller than normal for body-surface area in both sexes. The average LV mass Z-scores were significantly smaller for girls (P < 0.01) and marginally smaller for boys (P = 0.06). Girls had significantly smaller LV end-diastolic dimension Z-scores normalized to BSA (P < 0.01) compared to healthy controls and had significant increases in NT-proBNP. Four children developed SMNs as first events, a rate similar to historical controls.

Conclusions: Dexrazoxane prevented LV dysfunction and heart failure in children with OS receiving higher dose doxorubicin. However, LV structural changes were not fully prevented, especially in girls. As a result, hearts become abnormally small for body size, resulting in higher LV stress. Dexrazoxane did not increase the risk of SMN. Dexrazoxane should be used in this population, particularly for girls, to mitigate anthracycline-induced cardiotoxicity.

Trial registrations: ClinicalTrials.gov: NCT00003937 (P9754) registered 1 Nov 1999, and NCT00023998 (AOST0121) registered 13 Sept 2001.

Keywords: Cardiotoxicity; Doxorubicin; Osteosarcoma; Pediatrics.

PubMed Disclaimer

Conflict of interest statement

Competing interestsL.K. is an employee of the contract research organization Covance. M.K. is a consultant for Merck. K.J. has received travel reimbursement from Loxo oncology. R.G. has received laboratory research funding from Eisai. N.M. is an employee of Five Prime Therapeutics. P.M. has received travel reimbursement from Takeda and is a consultant for Eli Lilly and Astellas. S.L. is a consultant for Clinigen, a manufacturer of dexrazoxane, and Editor in Chief of Cardio-Oncology.

Figures

Fig. 1
Fig. 1
Changes in Left Ventricular End-Diastolic Dimension Z-scores in Patients, by Sex
Fig. 2
Fig. 2
Risk of Cardiomyopathy and Heart Failure, by NT-proBNP, among Patients Enrolled on P9754, by Time Since Completing Treatment and Sex. Cardiomyopathy and heart failure risk thresholds for this NT-proBNP assay in children with cardiomyopathy have been determined to be ≥100 pg/mL and ≥ 400 pg/mL, respectively [25, 26]. The y-axis of this figure shows the log transformed values of NT-proBNP. The horizontal lines indicating cardiomyopathy and heart failure thresholds correspond to 100 pg/mL and 400 pg/mL, respectively before they were log transformed
Fig. 3
Fig. 3
Risk of Cardiomyopathy and Heart Failure, as Assessed by by NT-proBNP, among Patients enrolled on the COG AOST0121 Study, by Sex.. Cardiomyopathy was defined by having a NT-proBNP ≥100 pg/mL and risk of heart failure was defined as an NT-proBNP ≥400 pg/mL [25, 26]. The y-axis of this figure shows the log [NT-proBNP]. The horizontal lines indicating cardiomyopathy and heart failure thresholds correspond to 100 pg/mL and 400 pg/mL, respectively before they were log transformed
Fig. 4
Fig. 4
5-year Cumulative Incidence of Second Malignant Neoplasms in The Clinical Trial INT-0133 versus COG P9754 and COG AOST0121
See this image and copyright information in PMC

References

    1. Meyers PA, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23(9):2004–2011. doi: 10.1200/JCO.2005.06.031. - DOI - PubMed
    1. Bielack SS, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776–790. doi: 10.1200/JCO.2002.20.3.776. - DOI - PubMed
    1. Smith MA, et al. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst. 1991;83(20):1460–1470. doi: 10.1093/jnci/83.20.1460. - DOI - PubMed
    1. Bansal Neha, Amdani Shahnawaz, Lipshultz Emma R., Lipshultz Steven E. Chemotherapy-induced cardiotoxicity in children. Expert Opinion on Drug Metabolism & Toxicology. 2017;13(8):817–832. doi: 10.1080/17425255.2017.1351547. - DOI - PubMed
    1. Getz Kelly D., Sung Lillian, Ky Bonnie, Gerbing Robert B., Leger Kasey J., Leahy Allison Barz, Sack Leah, Woods William G., Alonzo Todd, Gamis Alan, Aplenc Richard. Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children’s Oncology Group. Journal of Clinical Oncology. 2019;37(1):12–21. doi: 10.1200/JCO.18.00313. - DOI - PMC - PubMed

Associated data